• Something wrong with this record ?

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

AM. Lincoff, R. Mehran, TJ. Povsic, SL. Zelenkofske, Z. Huang, PW. Armstrong, PG. Steg, C. Bode, MG. Cohen, C. Buller, P. Laanmets, M. Valgimigli, T. Marandi, V. Fridrich, WJ. Cantor, B. Merkely, J. Lopez-Sendon, JH. Cornel, JD. Kasprzak, M....

. 2016 ; 387 (10016) : 349-56. [pub] 20151105

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16009911
E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

Links

PubMed 26547100
DOI 10.1016/s0140-6736(15)00515-2
Knihovny.cz E-resources

BACKGROUND: REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding. METHODS: We did a randomised, open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 225 hospitals in North America and Europe. We planned to randomly allocate 13,200 patients undergoing percutaneous coronary intervention in a 1:1 ratio to either REG1 (pegnivacogin 1 mg/kg bolus [>99% factor IXa inhibition] followed by 80% reversal with anivamersen after percutaneous coronary intervention) or bivalirudin. Exclusion criteria included ST segment elevation myocardial infarction within 48 h. The primary efficacy endpoint was the composite of all-cause death, myocardial infarction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation. The principal safety endpoint was major bleeding. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, identifier NCT01848106. The trial was terminated early after enrolment of 3232 patients due to severe allergic reactions. FINDINGS: 1616 patients were allocated REG1 and 1616 were assigned bivalirudin, of whom 1605 and 1601 patients, respectively, received the assigned treatment. Severe allergic reactions were reported in ten (1%) of 1605 patients receiving REG1 versus one (<1%) of 1601 patients treated with bivalirudin. The composite primary endpoint did not differ between groups, with 108 (7%) of 1616 patients assigned REG1 and 103 (6%) of 1616 allocated bivalirudin reporting a primary endpoint event (odds ratio [OR] 1·05, 95% CI 0·80-1·39; p=0·72). Major bleeding was similar between treatment groups (seven [<1%] of 1605 receiving REG1 vs two [<1%] of 1601 treated with bivalirudin; OR 3·49, 95% CI 0·73-16·82; p=0·10), but major or minor bleeding was increased with REG1 (104 [6%] vs 65 [4%]; 1·64, 1·19-2·25; p=0·002). INTERPRETATION: The reversible factor IXa inhibitor REG1, as currently formulated, is associated with severe allergic reactions. Although statistical power was limited because of early termination, there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin. FUNDING: Regado Biosciences Inc.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16009911
003      
CZ-PrNML
005      
20200323151828.0
007      
ta
008      
160408s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(15)00515-2 $2 doi
024    7_
$a 10.1016/S0140-6736(15)00515-2 $2 doi
035    __
$a (PubMed)26547100
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lincoff, A Michael $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA. Electronic address: lincofa@ccf.org.
245    10
$a Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial / $c AM. Lincoff, R. Mehran, TJ. Povsic, SL. Zelenkofske, Z. Huang, PW. Armstrong, PG. Steg, C. Bode, MG. Cohen, C. Buller, P. Laanmets, M. Valgimigli, T. Marandi, V. Fridrich, WJ. Cantor, B. Merkely, J. Lopez-Sendon, JH. Cornel, JD. Kasprzak, M. Aschermann, V. Guetta, J. Morais, PR. Sinnaeve, K. Huber, R. Stables, MA. Sellers, M. Borgman, L. Glenn, AI. Levinson, RD. Lopes, V. Hasselblad, RC. Becker, JH. Alexander, . ,
520    9_
$a BACKGROUND: REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding. METHODS: We did a randomised, open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 225 hospitals in North America and Europe. We planned to randomly allocate 13,200 patients undergoing percutaneous coronary intervention in a 1:1 ratio to either REG1 (pegnivacogin 1 mg/kg bolus [>99% factor IXa inhibition] followed by 80% reversal with anivamersen after percutaneous coronary intervention) or bivalirudin. Exclusion criteria included ST segment elevation myocardial infarction within 48 h. The primary efficacy endpoint was the composite of all-cause death, myocardial infarction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation. The principal safety endpoint was major bleeding. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, identifier NCT01848106. The trial was terminated early after enrolment of 3232 patients due to severe allergic reactions. FINDINGS: 1616 patients were allocated REG1 and 1616 were assigned bivalirudin, of whom 1605 and 1601 patients, respectively, received the assigned treatment. Severe allergic reactions were reported in ten (1%) of 1605 patients receiving REG1 versus one (<1%) of 1601 patients treated with bivalirudin. The composite primary endpoint did not differ between groups, with 108 (7%) of 1616 patients assigned REG1 and 103 (6%) of 1616 allocated bivalirudin reporting a primary endpoint event (odds ratio [OR] 1·05, 95% CI 0·80-1·39; p=0·72). Major bleeding was similar between treatment groups (seven [<1%] of 1605 receiving REG1 vs two [<1%] of 1601 treated with bivalirudin; OR 3·49, 95% CI 0·73-16·82; p=0·10), but major or minor bleeding was increased with REG1 (104 [6%] vs 65 [4%]; 1·64, 1·19-2·25; p=0·002). INTERPRETATION: The reversible factor IXa inhibitor REG1, as currently formulated, is associated with severe allergic reactions. Although statistical power was limited because of early termination, there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin. FUNDING: Regado Biosciences Inc.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a aptamery nukleotidové $x terapeutické užití $7 D052157
650    _2
$a koagulancia $x aplikace a dávkování $7 D003029
650    _2
$a léková alergie $x epidemiologie $7 D004342
650    _2
$a předčasné ukončení klinických zkoušek $7 D057239
650    _2
$a faktor IXa $x antagonisté a inhibitory $7 D015949
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x epidemiologie $7 D006470
650    _2
$a hirudiny $7 D006629
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oligonukleotidy $x aplikace a dávkování $7 D009841
650    _2
$a peptidové fragmenty $x terapeutické užití $7 D010446
650    12
$a koronární angioplastika $7 D062645
650    _2
$a rekombinantní proteiny $x terapeutické užití $7 D011994
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Severní Amerika $x epidemiologie $7 D009656
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mehran, Roxana $u Mount Sinai School of Medicine, New York, NY, USA.
700    1_
$a Povsic, Thomas J $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA.
700    1_
$a Zelenkofske, Steven L $u Regado Biosciences, Basking Ridge, NJ, USA.
700    1_
$a Huang, Zhen $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA.
700    1_
$a Armstrong, Paul W $u Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada. $7 gn_A_00008631
700    1_
$a Steg, P Gabriel $u Université Paris-Diderot, Sorbonne Paris Cité, Paris, France.
700    1_
$a Bode, Christoph $u University of Freiburg, Freiburg, Germany.
700    1_
$a Cohen, Mauricio G. $7 xx0246051 $u University of Miami Miller School of Medicine, Miami, FL, USA.
700    1_
$a Buller, Christopher $u St Michael's Hospital, Toronto, ON, Canada.
700    1_
$a Laanmets, Peep $u North Estonia Medical Centre, Tallinn, Estonia.
700    1_
$a Valgimigli, Marco $u University Hospital of Ferrara, Institute of Cardiology, Ferrara, Italy.
700    1_
$a Marandi, Toomas $u North Estonia Medical Centre, Tallinn, Estonia.
700    1_
$a Fridrich, Viliam $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia.
700    1_
$a Cantor, Warren J $u Southlake Regional Health Centre, Newmarket, ON, Canada.
700    1_
$a Merkely, Bela $u Semmelweis University Heart and Vascular Center, Budapest, Hungary.
700    1_
$a Lopez-Sendon, Jose $u Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
700    1_
$a Cornel, Jan H $u Medical Center Alkmaar, Alkmaar, Netherlands.
700    1_
$a Kasprzak, Jaroslaw D $u Medical University of Lodz, Bieganski Hospital, Lodz, Poland.
700    1_
$a Aschermann, Michael $u General University Hospital, Prague, Czech Republic. $7 nlk19990072993
700    1_
$a Guetta, Victor $u Heart Institute Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.
700    1_
$a Morais, Joao $u Santo Andre's Hospital, Leiria, Portugal.
700    1_
$a Sinnaeve, Peter R $u University Hospitals Leuven Campus Gasthuisberg, Leuven, Belgium.
700    1_
$a Huber, Kurt $u Wilhelminen Hospital, Vienna, Austria.
700    1_
$a Stables, Rod $u Liverpool Heart & Chest Hospital, Liverpool, UK.
700    1_
$a Sellers, Mary Ann $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA.
700    1_
$a Borgman, Marilyn $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA.
700    1_
$a Glenn, Lauren $u Regado Biosciences, Basking Ridge, NJ, USA.
700    1_
$a Levinson, Arnold I $u Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Lopes, Renato D $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA.
700    1_
$a Hasselblad, Vic $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA.
700    1_
$a Becker, Richard C $u University of Cincinnati College of Medicine, Cincinnati, OH, USA.
700    1_
$a Alexander, John H $u Duke Clinical Research Institute, Duke Medicine, Durham, NC, USA. $7 gn_A_00003908
700    1_
$a ,
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 387, č. 10016 (2016), s. 349-56
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26547100 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20200323152256 $b ABA008
999    __
$a ok $b bmc $g 1113340 $s 934279
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 387 $c 10016 $d 349-56 $e 20151105 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options